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http:WHAT THIS PAPER ADDS
Open repair of abdominal aortic para-anastomotic aneurysms (PAAs) and pseudoaneurysms (PSAs) after
infrarenal abdominal aortic aneurysm open repair is burdened by increased challenges and complications
related to the redo procedure. Complex endovascular techniques (fenestrated/branched, chimney, and peri-
scope parallel grafts) have been developed in the last decade in order to treat these lesions; however, larger
series are currently still limited, long-term follow-up is poorly known, patient customization (making the
treatment unavailable in emergency) may be required, and treatment cost is often high. As a result, the standard
use of commercially-available abdominal endovascular devices is nowadays one of the most appealing options,
routinely performed whenever possible in most centers. However, in the analysis of previous series of PAAs and
PSAs treated with standard commercially-available abdominal endovascular devices, the anatomical inclusion
criteria were usually not speciﬁcally deﬁned and the series included various off-label uses of the devices. In our
study, we speciﬁcally analyzed the feasibility and outcomes only of strict on-label use of the devices (OnL-
endovascular aortic repair [EVAR]) for the treatment of abdominal PAAs and PSAs. Our analysis conﬁrmed both
limited feasibility of OnL-EVAR and high rates of late complications and reinterventions.Objectives: To analyze feasibility and outcomes of endovascular aortic repair (EVAR) with a strictly on-label use of
abdominal aortic endografts (OnL-EVAR) to treat para-anastomotic aneurysms (PAAs) and pseudoaneurysms
(PSAs) after infrarenal abdominal aortic aneurysm open repair (OR).
Methods: The data of all consecutive patients treated between 1999 and 2012 for non-infected abdominal PAAs
and PSAs at our center were prospectively collected. All cases ﬁt for EVAR based on the instructions for use of a
series of abdominal aortic endografts commercially available during the study period were scheduled for OnL-
EVAR regardless of patients’ surgical risk. Any patients unﬁt for OnL-EVAR underwent OR or other complex
endovascular techniques.
Results: One hundred and forty-three patients were collected; 78 underwent OR and 65 endovascular repair with
different strategies. Coil embolization, hybrid, and chimney/periscope grafts techniques were limited to seven
patients unﬁt both for OR and OnL-EVAR. Inclusion criteria for OnL-EVAR were reached in 58 patients for an
overall OnL-EVAR feasibility of approximately 40% (21% for PAAs and 55% for PSAs). In particular, OnL-EVAR
feasibility was 19% in case of involvement of proximal aortic anastomosis, 71% for distal aortic anastomosis, and
80% for iliac arteries. Overall, 25 aortouniiliac and 11 bifurcated implants were performed, single proximal aortic
cuffs were used in 10 patients, and iliac extension in 12. Primary technical success was 98% without perioperative
mortality. At a median follow-up of 67 months (range: 1e144 months), cumulative aneurysm-related mortality
was 7%, endograft migration 7%, and reintervention was 17%. Life-table analysis showed actuarial survival and
freedom from aneurysm-related death at 1, 3, and 5 years of 100%, 98%, and 95%, and of 100%, 98%, and 95%,
respectively. Freedom from aortic reintervention or open conversion at 1, 3, and 5 years was 94%, 90%, and 85%.
Conclusions: Feasibility of OnL-EVAR was limited for PAAs and PSAs, with a rate that was lower than 20% in case
of involvement of proximal aortic anastomosis. Aortouniiliac conﬁguration was the most commonly feasible
implant and, despite strict on-label use of abdominal devices, the rate of late complications and reinterventions
was high.
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anastomotic aneurysm, PseudoaneurysmINTRODUCTION
Abdominal aortic aneurysm (AAA) open repair is generally
considered as safe and durable. However, this procedure is
burdened by the risk of some long term complications, such
as para-anastomotic aneurysms (PAAs) and pseudoaneur-
ysms (PSAs).1e9
PAAs and PSAs are deﬁned as aneurysm formation near
the anastomotic line either proximal or distal to the im-
plantation of a graft. According to Haimovici,7 PAAs are
enclosed by uninterrupted arterial wall components, and
they may represent a residual lesion or more likely the
progression of aneurysmal disease, while PSAs are charac-
terized by breaks in the arterial wall with extravasation in
surrounding tissues and the formation of a ﬁbrous capsule
that gradually expands with blood pressure.
The PAAs and PSAs following AAA open repair range from
0.5% to 15.0% in different series,8,9 and are both potentially
fatal conditions as they may lead to aortic rupture,
bleeding, or even infection and ﬁstulization within the
duodenum.1,5,6,8,9
Conventional treatment of para-anastomotic aneurysms
and PSAs is open surgical repair (OR) and is burdened with
perioperative mortality ranging from 4.5% to 67.0%.10e13
Over the last two decades endovascular aortic repair
(EVAR) has emerged as a promising alternative to OR with
reduced early morbidity and mortality.14,15 However, the
feasibility of standard device-based endovascular technol-
ogy with the on-label use of commercially-available
endografts (OnL-EVAR) is limited, especially for the prox-
imity of renal arteries to the failed proximal aortic anasto-
mosis. As a result, branched endovascular technology,16,17
chimney/periscope (CHIMPS),18,19 and “hybrid” tech-
niques20,21 have been developed over the last few years in1. Clinical manifestations and preoperative risk factors of on-lab
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dipyridamole thallium ororder to treat abdominal aortic lesions near to renal and
visceral arteries; however, indications and long-term results
are debated and costs are high.
The aim of this study is to investigate the feasibility rate
and outcomes of OnL-EVAR for PAAs and PSAs after prior
AAA open repair in a single-center setting.METHODS
We performed a retrospective analysis of prospectively
collected data of all consecutive patients who underwent
open or endovascular repair for PAAs or PSAs (aortic or
iliac) following previous OR for atherosclerotic AAA. All
cases with suspected graft infection and/or aorto-enteric
ﬁstula were excluded from the study. All cases available
for OnL-EVAR based on the manufacturer’s instructions for
use (IFU) were scheduled for EVAR regardless of the surgical
risk of the patient. Any patients unﬁt for OnL-EVAR were
treated with conventional OR whenever possible; cases
unﬁt both for OR and OnL-EVAR were treated with alter-
native strategies, such as coil embolization, CHIMPS, and
“hybrid” techniques. No cases of custom-made fenestrated
or branched endografts were used in the study period to
treat PAAs or PSAs.
Data were collected from clinical and radiological records,
and entered onto a computerized database. Demographics,
clinical manifestations, and preoperative risk factors of pa-
tients who underwent OnL-EVAR (summarized in Table 1)
were reported according to the Society for Vascular Surgery
Suggested Reporting Standards22 and to the Society for
Vascular Surgery/American Association for Vascular Surgery
medical comorbidity grading system.23
All patients underwent a preoperative contrast-enhanced
computed tomography angiography (CTA). Preoperativeel endovascular aortic repair (OnL-EVAR) study group.
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Table 1-continued
OnL-EVAR (%)
2 Any one of the following: stable angina, no
angina but signiﬁcant reversible perfusion defect
on dipyridamole thallium scan, signiﬁcant silent
ischemia (1% of time) on Holter monitoring,
ejection fraction 25e45%, controlled ectopy or
asymptomatic arrhythmia, or history of
congestive heart failure that is now well
compensated
19 (32)
3 Any one of the following: unstable angina,
symptomatic or poorly controlled ectopy/
arrhythmia (chronic/recurrent), poorly
compensated or recurrent congestive heart
failure, ejection fraction <25%, myocardial
infarction within 6 months
25 (43)
Renal statusb
Stage 1 (GFR 90)
(kidney damage with normal or [GFR)
11 (19)
Stage 2 (GFR 60e89)
(kidney damage with mild YGFR)
29 (49)
Stage 3 (GFR 30e59)
(moderate YGFR)
10 (18)
Stage 4 (GFR 15e29)
(severe YGFR)
5 (9)
Stage 5 (GFR <15 of dialysis)
(kidney failure)
3 (5)
Pulmonary status
0 Asymptomatic, normal chest X-ray ﬁlm, PFTs
20%
4 (7)
1 Mild dyspnea on exertion or mild X-ray
parenchymal changes, PFTs 65e80%
8 (14)
2 Between 1 and 3 20 (34)
3 VC < 1.85 L, FEV1 <1.2 L or <35%,
pCO2 > 45 mmHg, pulmonary hypertension
26 (45)
Hypertension
0 (Diastolic <90 mmHg) 2 (3)
1 (Easily controlled, single drug) 12 (20)
2 (Requires two drugs) 38 (65)
3 (>Two drugs or uncontrolled) 6 (10)
Note. GU tract ¼ genitourinary tract; GI tract ¼ gastrointestinal tract; GFR ¼ estimated glomerular ﬁltration rate; PFTs ¼ pulmonary
function tests; VC ¼ vital capacity; FEV1 ¼ forced expiratory volume in 1 second; pCO2 ¼ partial pressure of CO2.
a Major cardiac complication rates.
b Stages of chronic kidney disease.
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angulation, aortic bifurcation diameter, iliofemoral access,
overall implant length, and presence of thrombus and cal-
ciﬁcations was performed with analogic systems or a variety
of post-processing software until 2008, and then from 2009Table 2. Instructions for use (IFUs) and frequency of employment of s
Stent-graft Brand n (%) cases in this series
Excluder Gore 3 (5)
Zenith Flex Cook 32 (56)
Zenith LP Cook 3 (5)
Talent Medtronic 10 (17)
Endurant Medtronic 7 (12)
Vanguard Boston Scientiﬁc 3 (5)OsiriX (Pixmeo, Bernex, Switzerland) using multiplanar
reconstruction tools was employed.
All endovascular procedures were performed in the
operating room equipped for open surgical conversion using
a portable C-arm (Moonray Simad Medical Technology,tent-grafts used in this series.
IFU
Aortic neck length (mm) Aortic neck angulation
15 60
15 60
15 60
10 60
10/15 60/75
15 d
Table 3. Stent-graft used for para-anastomotic aneurysm (PAA)
and pseudoaneurysm (PSA) treatment in the on-label
endovascular aortic repair (OnL-EVAR) group and type of surgical
reconstruction performed in the open surgical repair (OR) group.
PAA PSA
OnL-EVAR (n [ 58)
Bifurcated 1 10
Aortouniliac 3 22
Aortic cuff 5 5
Iliac cuff 2 10
OR (n [ 78)
Aorto-aortic 19 14
Aorto-bifemoral 21 24
660 Y. Tshomba et al.Mirandola (Mo), Italy, or Ziehm-Vision RFD Ziehm Imaging,
Nuremberg, Germany)).
Patients were approached in most cases through a uni- or
bilateral groin incision. Extraperitoneal iliac access was
required in two cases (3%) for severely diseased iliac axis.
Adjunctive brachial or radial access was usually per-
formed in case of involvement of proximal anastomosis for
catheterization of the lower renal artery in order to attempt
rescue endovascular maneuvers in case of its unintentional
covering.
Iopamidol 370 mg/ml (Iopamiro 370; Bracco, Milano,
Italy) was used in all patients with serum creatinine
<0.9 mg/dL, while Iodixanol 320 mgI/ml (Visipaque, GE
Healthcare, Buckinghamshire, UK) was used in all patients
with serum creatinine >1 mg/dL, but renal status <2.18
Intravenous heparin (70 IU/kg) was administered after
introducer insertion.
Implanted abdominal aortic commercially-available off-
the-shelf endografts were
 Excluder (W.L. Gore & Associates, Flagstaff, AZ, USA);
 Zenith (Cook Inc, Bloomington, IN, USA);Figure 1. On the left is shown a preoperative computed tomograph
pseudoaneurysm following aorto-bi-iliac reconstruction; of note, bilate
the endovascular repair using an aortouniiliac stent graft with contral Talent abdominal and Endurant (Medtronic, Minneapolis,
MN, USA);
 Vanguard (Boston Scientiﬁc/Scimed, Natick,
Massachusetts).
Planned endograft oversizing was strictly determined
according to the manufacturer’s IFU. IFU and volume of use
in the study period of all devices are reported in Table 2.
The use of endografts with suprarenal ﬁxation systems was
largely preferred in cases of proximal PAA and PSA
(Table 2).
Endografts were always delivered over a stiff 0.03500
guidewire (Amplatz Super Stiff, Boston Scientiﬁc, Miami, FL,
USA; Lunderquist Extra Stiff, Cook) with ballooning accord-
ing to manufacturer’s IFU.
Completion angiography after stiff guidewire removal
was always performed to assess patency of the renal ar-
teries and to discover endoleak or other technical
concerns.
Patients were followed-up with CTA, duplex ultrasound,
and clinical examination at 1 month and annually thereafter.
All-cause late mortality and complications were identiﬁed
through a review of ofﬁce charts and telephone
assessment.
Continuous variables were reported as means and SDs,
and dichotomous variables were reported as percentages.
The KaplaneMeier method was used to estimate survival.
Analyses were run using IBM SPSS Statistics 18 software
(SPSS, Chicago, IL, USA).
RESULTS
In our center 4,539 AAA open repairs (between 1993 and
2012) and 835 EVAR (between 1999 and 2012) were per-
formed overall. From 1999, 143 consecutive patients
treated for PAA or PSA were found. Proximal anastomosisy scan with three-dimensional (3D) reconstruction of a multiple
ral hypogastric occlusion. On the right a postoperative 3D image of
ateral occlusion and femoro-femoral bypass grafting.
Figure 2. Pre-operative computed tomography images and three-dimensional reconstruction of a ruptured proximal aortic pseudoa-
neurysm after aorto-aortic reconstruction in a patient with bilateral double renal arteries.
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(23%) lesions, and iliac arteries in 32 (19%) lesions for a
total of 165 lesions in 143 patients. The index procedure
was performed in our center in 61% of cases. The median
delay from index to redo procedure was 8 years (range: 0e
18). Seventy-eight patients underwent OR (Table 3) and 65Table 4. Intraoperative and early postoperative complications of
patients who underwent on-label endovascular aortic repair
(OnL-EVAR).
OnL-EVAR
Total procedures 58
Procedural time (mins) 65 (range 38e93)
Blood loss (mL) 220 (range 50e350)
ICU stay (h) 6 (range 0e35)
Length of stay (days) 2 (range 1e4)
Technical success 57 (98%)
Type I endoleak 3 (5%)
Type II endoleak 1 (1.7%)
Perioperative mortality 0
Respiratory failure 4 (7%)
Renal failurea 6 (10%)
AMI 3 (5%)
Ileus 0
Gluteal claudication 2 (3%)
Hemorrhagic complications 0
Note. ICU ¼ intensive care unit; AMI ¼ acute myocardial
infarction.
a Renal failure was doubling of preoperative serum creatinine.endovascular repair with different strategies. Off-label
complex endovascular techniques were used in seven
casesdall PAAs involving the proximal aortic anastomosis
(periscope or chimney grafts in six cases, and coil emboli-
zation through a bare metal aortic stent in one case). In-
clusion criteria for OnL-EVAR were reached in 58 patientsFigure 3. KaplaneMeier curve shows overall survival after on-label
endovascular aortic repair (OnL-EVAR) of para-anastomotic aneu-
rysm and pseudoaneurysm repair.
Figure 4. KaplaneMeier curve shows freedom from aneurysm-
related death after on-label endovascular aortic repair (OnL-
EVAR) for all stent grafts that were used.
662 Y. Tshomba et al.(Table 3), for an overall OnL-EVAR feasibility of 40% (21%
for PAAs and 55% for PSAs). In particular, OnL-EVAR feasi-
bility was 19% in the case of involvement of proximal aortic
anastomosis, 71% for distal aortic anastomosis, and 80% for
iliac arteries. The OnL-EVAR groups’ proximal anastomosis
was involved in 18 (26%) lesions, aortic bifurcation in 27
(38%) lesions, and iliac arteries in 23 (36%) lesions for a
total of 70 lesions in 58 patients. Aortouniliac conﬁguration
was used in 25 cases (Fig. 1), bifurcated in 11 cases (Fig. 2),
aortic cuff in 10 cases, and iliac cuff in 12 cases (Table 3).
Four polar renal arteries were intentionally overstented,
and no cases of unintentional main renal arteries over-
stenting were reported. In most iliac PSAs or PAAs, an
intentional overstenting of a hypogastric artery was per-
formed, mainly after previous endovascular hypogastricFigure 5. Freedom from aortic reintervention or open conversion
after on-label endovascular aortic repair (OnL-EVAR) for all stent
grafts used.artery occlusion with an Amplatzer Vascular Plug (AGA
Medical, Plymouth, MN, USA) in order to prevent type II
endoleak.
A type I endoleak was detected upon intraoperative
angiography immediately after endograft deployment in
three cases (5%) and it was corrected in two cases after
intraoperative endograft ballooning. A secondary procedure
of cuff re-lining with a bare metal stent (Jotec E-XL,
Hechingen, Germany) was performed on the patient with
the uncorrected type I endoleak after endovascular exclu-
sion of a proximal symptomatic PAA by means of an aortic
cuff. For persistent ruptured pseudoaneurysm perfusion,
the patient underwent open conversion with cuff removal
and aortic repair with a Dacron tube graft after 5 days. In
one case (2%), a type II endoleak was intraoperatively
detected but resolved spontaneously at 30 days (as seen on
CTA). No perioperative mortality was recorded, and early
results and morbidity are summarized in Table 4. In
particular, after OnL-EVAR, transient doubling of serum
creatinine never requiring dialysis was observed in six cases
(10%) and perioperative bowel ischemia in three cases (5%).
Bowel ischemia was suspected in any case of abdominal
pain, peritoneal irritation, nausea, vomiting, and diarrhea
associated with positive laboratory tests (persistent arterial
blood pH <7.34; plasma lactate level >2.1 mmol/L; white
blood cell count >12,000/mL). In all the cases the clinical
suspicion of bowel ischemia was conﬁrmed at early post-
operative colonoscopy and was medically resolved.
At a median follow-up of 67 months (range: 1e144
months), the cumulative all-cause and aneurysm-related
mortality was 15% (nine patients) and 7% (four patients),
respectively. Life-table analysis showed actuarial survival
and freedom from aneurysm-related death at 1, 3, and 5
years of 100%, 98%, and 95%, and of 100%, 98%, and 95%,
respectively (Figs. 3 and 4). Freedom from aortic reinter-
vention or open conversion at 1, 3, and 5 years was 94%,
90%, and 85%, respectively (Fig. 5).
Late migration was observed in four single proximal
aortic cuffs among 10 implanted, and in all cases a supra-
renal ﬁxation was present. The overall cumulative late
reintervention rate was 17%, with a rate of 40% after the
use of proximal aortic cuff, 27% after the use of bifurcated
endografts, 8% after the use of aortouniiliac endografts and
8% after the use of iliac extensions. Five patients were
treated for secondary type I endoleak, four for aorto-iliac
malperfusion, and one for secondary type III endoleak as
summarized in Table 5. In particular, four late open surgical
procedures were performed: two patients underwent
emergency surgical iliofemoral thrombectomy and stenting;
one patient underwent an extra-anatomic axillo-bifemoral
bypass grafting; and one patient underwent cuff removal
and juxtarenal aorto-bifemoral bypass graft through a redo-
laparotomy (Fig. 6).DISCUSSION
Open repair of PAAs and PSAs represents a challenging
procedure not only because re-dissection through scarred
Table 5. Cause of secondary failure and type of treatment of patients who underwent reintervention and/or conversion during follow-up.
Patient Treatment option of PAA/PSA Cause of secondary failure Treatment of secondary failure
1 Proximal cuff Distal migration and type I EL Axillobifemoral bypass
2 Proximal cuff Distal migration and type I EL Cuff removal and aortic repair
3 Bifurcated Neck enlargement and proximal type I EL Proximal cuff
4 Proximal cuff Distal migration and aortoiliac occlusion Aortouniiliac þ crossover
5 Proximal cuff Distal migration and aortoiliac occlusion Aortouniiliac þ crossover
6 Aortouni-iliac Iliac branch occlusion Iliac recanalization
7 Bifurcated Iliac branch occlusion Iliac recanalization
8 Aortouniiliac Modular de connection and type III EL Aortouniiliac relining
9 Bifurcated Neck enlargement and proximal type I EL Aortouniiliac þ crossover
10 Iliac extension Distal migration and type I EL Bifurcated implant
Note. PAA ¼ para-anastomotic aneurysm; PSA ¼ pseudoaneurysm; OR ¼ open surgical repair; EL ¼ endoleak.
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commonly required,24e26 but also for speciﬁc issues related
to the limited infrarenal neck length available in redo
procedure.
Standard technique for infrarenal AAA OR requires the
juxtarenal positioning of the aortic clamp with the anasto-
mosis performed as near as possible to the lower renal
artery. The rationale of this strategy is to perform the
anastomosis on the aortic tissue in the strongest and
healthiest state possible.8 The usual thickness of the
abdominal aortic clamps we used (Medicon,Wertheim “AT”
clamp 24.5 cm [9 3/4
00]) ranged from 3 to 5 mm. This means
that when a PAA and a PSA involves the proximal anasto-
mosis, the infrarenal aortic neck is a few millimeters longer
than the clamp thickness. For this reason, the aortic neck is
not usually enough to allow a safe infrarenal redo-clamping
and redo-anastomosis and often an inter- or suprarenalFigure 6. Preoperative computed tomography scan with three-dimens
previously treated for a proximal para-anastomotic aneurysm; of note
doaneurysm reperfusion (yellow arrow).aortic clamping is required with increased risk of renal and
visceral complications.27,28
EVAR has emerged over the last two decades as a valid
and safe alternative to OR for AAA,29,30 and it would be
particularly appealing in cases of PAAs and PSAs, where
there is the potential to avoid retroperitoneal re-dissection
and suprarenal clamping.
Also, in EVAR cases, the infrarenal neck length is a critical
issue and one of the main inclusion criteria for on-label
endograft use together with the neck angulation. The me-
dian infrarenal neck length required by the commercially-
available endografts used in our center in the study
period ranges from 10 to 15 mm (Table 2). This is the clear
reason why, if proximal anastomosis during index open
repair were performed with aortic clamp in juxtarenal po-
sition, the infrarenal neck length would not usually be
enough for OnL-EVAR.ional reconstruction of an aortic cuff distal migration in a patient
in axial sections and in the multiplanar reconstruction the pseu-
664 Y. Tshomba et al.In analyzing the results of previous series of PAA and PSA
EVAR performed with standard commercially-available de-
vices, the anatomical inclusion criteria were not clearly
deﬁned, and various off-label uses of the devices were
included, such as thoracic endografts used in abdominal aorta
or abdominal devices deployed in neck length shorter than IFU
recommendations.14,31e33 Consequently, and not surprisingly,
Ten Bosch et al.31 have recently reported disappointing out-
comes at a median follow up of 41 months with rates of
reintervention and conversion of 26.9% and 6.9%, respec-
tively. Van Herwaarden et al.32 also reported a rate of con-
version of 14.3% (all patients treated with tube grafts) at a
median follow up of 12 months, and Sachdev et al.14 reported
an endoleak rate of 11% within 1 month of procedure.14
In our study, we analyzed a series of patients who un-
derwent PAA and PSA EVAR only through the strict on-label
use of commercially-available abdominal devices. Short and
angulated necks not matching the IFU of devices were
excluded from our study. Our analysis conﬁrmed limited
feasibility of OnL-EVAR and, interestingly, reported unex-
pectedly high rates of late complications and reinterven-
tions, despite the strict on-label use of the devices. The
increased risk of endograft migration from an “in-graft”
polyester landing zone has already been reported31 and
this, together with the poor quality of the aortic wall and
the increased risk of neck enlargement that may be hy-
pothesized in patients developing a PAA or a PSA, may
explain these poor results. Neither device-related pro-
pensity of late complications nor speciﬁc protection from
device migration of suprarenal ﬁxation emerged in our se-
ries, perhaps because of the small size of the sub-groups.
However, poor outcomes with the use of single proximal
aortic cuffs with especially high risk of migration (40%) were
reported. In our series, the highest rate of on-label implants
was with aortouniiliac endografts. This approach was
needed in most cases of previous aorto-bi-iliac or bifemoral
reconstruction because in the index procedure a very short
main graft body (2e3 cm) would not allow the deployment
either of a cuff or of bifurcated endografts. In the cases of
PAA or PSA involving distal anastomosis in patients with a
previous tube-graft repair, an aortouniiliac implant was
frequently needed for the tube graft diameter (we
commonly use a 14e16-mm diameter graft), which does
unusually allow for the correct opening and expansion of
two iliac limbs of a bifurcated endograft. Some new,
commercially-available bifurcated endografts allow for a
good opening of both the iliac limbs, even within distal
aortic diameter of 15 mm, and this could enlarge the in-
dications to bifurcated endografts in the next series.
Instructions for use of most commercially-available
endografts have changed over the last decade, and inclu-
sion criteria for OnL-EVAR in our study match the anatomical
criteria and refer to the commercially-available devices at the
time of procedure, so that current technological improve-
ments and indications were missed by our analysis. Even the
lack of sophisticated CTA before 2008 and of the post-
processing software, which are currently available, may
have biased our study, with a reduced accuracy ofpreoperative planning before 2008. Furthermore, additional
tools are now available that improve primary technical suc-
cess of EVAR with standard devices in the case of short and
angulated neck, such as the use of giant stents or endoan-
chors, without the need for chimney techniques or fenes-
trated endografts.34 Palmaz XL stent (Cordis, Miami Lakes, FL,
USA) is a one-piece laser-cut stainless steel slotted tube,
available in 40 and 50 mm lengths that can be expanded
between 14 and 25 mm, and has been proposed to support
EVAR in difﬁcult proximal necks.35 Self-expandable stents are
also now available on the market for endograft re-lining,
combining the outward radial force of self expandable stent
design with open cells. In particular, ﬂexibility of these de-
vices may help endograft remodeling in tortuous short
landing zones.36 Endostaples or endoanchors are also
designed to replicate the function of an interrupted aortic
suture, and have been proposed and tested to perform
endograft ﬁxation in angulated infrarenal aortic neck.37 In
this setting the use of single cuff both to exclude PSAs or PAAs
and to ﬁx prior endografts may be disappointing. In this
setting the problem is that the prior endograftsmay persist to
migrate, leading to disconnection and huge type III endo-
leaks. Securement of the endografts to the aortic wall, as well
as to the proximal cuff, has the potential to improve long-
term results and should be investigated in the future.
In the meantime, fenestrated or branched endografts
implantation has been proven to be safe and feasible in
proximal PAAs and juxtarenal aneurysms, with several large
series conﬁrming satisfactory intermediate-term out-
comes.38e40 However, these techniques require
manufacturing delay of custom endografts, making them
unsuitable for an emergency setting and are rather expen-
sive.14,15,31,33 CHIMPS techniques also offer an appealing
alternative based on already existing materials that are
usually readily available, although mid- and long-term re-
sults are yet to be evaluated.19,41,42
Regarding OnL-EVAR in the case of PAAs and PSAs
involving iliac anastomosis, the rate of feasibility with stan-
dard abdominal devices in our series was satisfactory,
reaching 80%, mainly through the use of iliac limbs or ex-
tensions. Only one late complication was reported in a pa-
tient who had successfully undergone a secondary
endovascular procedure. However, this high rate of feasibility
would have been strongly reduced in this subgroup of pa-
tients if sparing of hypogastric arteries had been always
planned. Overstenting of hypogastric arteries has been pre-
viously reported to be related to risk of buttock claudication
and bowel ischemia,43e45 and in our series, three cases of
bowel ischemia, all medically resolved, were reported after
overstenting of one hypogastric artery. It is well known how
safe and effective speciﬁcally-designed branched endog-
rafts46 are in both aneurysm exclusion and saving hypogastric
artery patency with reasonable costs and logistics.CONCLUSION
Despite reduced anatomical feasibility, the use of
commercially-available abdominal endovascular devices to
European Journal of Vascular and Endovascular Surgery Volume 46 Issue 6 p. 657e666 December/2013 665treat proximal PAAs and PSAs after AAA open repair is a
very appealing option nowadays, routinely performed
whenever possible in most centers. A deeper understanding
of early and late outcomes, and possible complications of
these procedures is therefore mandatory, and based on
early and late results reported in the present study, a
careful follow up would be necessary for the high risk of late
complications and reinterventions, even after the strict on-
label use of abdominal devices in these patients.
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